Alpaslan 2015.

Methods	A patient report of stuttering associated with the use of methylphenidate
Participants	Diagnosis of ADHD: DSM‐5 (subtype: predominantly hyperactive‐impulsive) Age: 7 years old IQ: 94 Sex: male Methylphenidate naïve: yes Ethnicity: white/Turkish Country: Turkey Comorbidity: none Comedication: none Sociodemographics: both parents had advanced no further than elementary school. The parents' history was unremarkable
Interventions	Short‐acting methylphenidate 10 mg/daily Administration schedule: not stated Duration of treatment: 4 weeks Treatment compliance: good according to regular visits record
Outcomes	Non‐serious adverse events: 10 days after beginning short‐acting methylphenidate treatment, the client began to stutter. Treatment was stopped. 1 week later, the patient's speech was back to normal. 4 weeks later atomoxetine treatment was started with no reoccurrence of stuttering
Notes	Key conclusions of the study authors: evidence for stuttering associated with the use of short‐acting methylphenidate is presented. Clinicians should be aware that an additional adverse effect of methylphenidate may be a beginning of a stutter Funding/vested interest: the authors received no financial support for the research and/or authorship of this article. The authors report no conflicts of interest Supplemental information regarding IQ, ethnicity and treatment compliance received through personal email correspondence with the authors in April 2016 (Alpaslan 2016 [pers comm])